BRCA1, BRCA2, AR and IGF-I expression in prostate cancer: Correlation between RT-qPCR and immunohistochemical detection

Oncology Reports

Volumn 26, Issue 3, 2011, Pages 695-702

  Rabiau, Nadège ^a,d,e   Déchelotte, Pierre ^c,f   Adjakly, Mawussi ^a,d   Kemeny, Jean Louis ^b,c   Laurent, G U Y ^b   Boiteux, Jean Paul ^b   Kwiatkowski, Fabrice ^a,d   Bignon, Yves Jean ^a,c,d   Bernard Gallon, Dominique ^a,d  

^a CENTRE JEAN PERRIN   (France)

^b SERVICE DE RHUMATOLOGIE   (France)

^c UNIVERSITÉ CLERMONT AUVERGNE   (France)

^d CRNH AUVERGNE   (France)

^e Soluscience SA   (France)

^f UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

Author keywords

Androgen receptor; BRCA; IGF I; Immunohistochemistry; Prostate cancer; Real time quantitative PCR

Indexed keywords

MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; AR GENE; ARTICLE; BRCA2 GENE; CANCER DIAGNOSIS; CANCER RISK; CONTROLLED STUDY; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC CORRELATION; HUMAN; HUMAN TISSUE; IGF 1 GENE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; QUANTITATIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA; AGED; BRCA1 PROTEIN; BRCA2 PROTEIN; GENE EXPRESSION; HUMANS; IMMUNOENZYME TECHNIQUES; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 79960012607     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1339     Document Type: Article

References (47)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. Colonna M, Danzon A, Delafosse P, et al: Cancer prevalence in France: time trend, situation in 2002 and extrapolation to 2012. Eur J Cancer 44: 115-122, 2008.
3. Hill C and Doyon F: [The frequency of cancer in France in year 2000, and trends since 1950]. Bull Cancer 92: 7-11, 2005.
4. Simard J, Dumont M, Labuda D, et al: Prostate cancer susceptibility genes: lessons learned and challenges posed. Endocr Relat Cancer 10: 225-259, 2003. (Pubitemid 36763535)
5. Hoffman RM, Gilliland FD, Eley JW, et al: Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst 93: 388-395, 2001. (Pubitemid 32229383)
6. Ablin RJ, Bronson P, Soanes WA and Witebsky E: Tissue- and species-specific antigens of normal human prostatic tissue. J Immunol 104: 1329-1339, 1970.
7. Chodak G: Prostate cancer: epidemiology, screening, and biomarkers. Rev Urol 8 (Suppl 2): S3-S8, 2006.
8. Miller DC, Hafez KS, Stewart A, Montie JE and Wei JT: Prostate carcinoma presentation, diagnosis, and staging: an update form the National Cancer Data Base. Cancer 98: 1169-1178, 2003. (Pubitemid 37099901)
9. Thompson IM, Pauler DK, Goodman PJ, et al: Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 350: 2239-2246, 2004.
10. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M and Downs J The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol 172: 1297-1301, 2004. (Pubitemid 39249701)
11. Lapointe J, Li C, Higgins JP, et al: Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 101: 811-816, 2004. (Pubitemid 38121040)
12. Norberg M, Egevad L, Holmberg L, Sparen P, Norlen BJ and Busch C: The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. Urology 50: 562-566, 1997. (Pubitemid 27433216)
13. Fournier G, Valeri A, Mangin P and Cussenot O: [Prostate cancer. Epidemiology. Risk factors. Pathology]. Ann Urol (Paris) 38: 187-206, 2004 (In French).
14. Yoshida K and Miki Y Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci 95: 866-871, 2004. (Pubitemid 40045520)
15. Rauh-Adelmann C, Lau KM, Sabeti N, Long JP, Mok SC and Ho SM: Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines. Mol Carcinog 28: 236-246, 2000.
16. Mitra A, Fisher C, Foster CS, et al: Prostate cancer in male BRCAl and BRCA2 mutation carriers has a more aggressive phenotype. Br J Cancer 98: 502-507, 2008. (Pubitemid 351161242)
17. Fan S, Wang JA, Yuan RQ, et al: BRCA1 as a potential human prostate tumor suppressor: modulation of proliferation, damage responses and expression of cell regulatory proteins. Oncogene 16: 3069-3082, 1998. (Pubitemid 28297729)
18. Yuli C, Shao N, Rao R, et al: BRCA1a has antitumor activity in TN breast, ovarian and prostate cancers. Oncogene 26: 6031-6037, 2007.
19. Rosen EM, Fan S, Pestell RG and Goldberg ID: BRCA1 in hormone-responsive cancers. Trends Endocrinol Metab 14: 378-385, 2003.
20. Yeh S, Hu YC, Rahman M, et al: Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells. Proc Natl Acad Sci USA 97: 11256-11261, 2000.
21. Shaneyfelt T, Husein R, Bubley G and Mantzoros CS: Hormonal predictors of prostate cancer: a meta-analysis. J Clin Oncol 18: 847-853, 2000. (Pubitemid 30106616)
22. Brown CJ, Goss SJ, Lubahn DB, et al: Androgen receptor locus on the human X chromosome: regional localization to Xq11-12 and description of a DNA polymorphism. Am J Hum Genet 44: 264-269, 1989. (Pubitemid 19045022)
23. Giovannucci E, Stampfer MJ, Krithivas K, et al: The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA 94: 3320-3323, 1997. (Pubitemid 27157309)
24. Latil A, Bieche I, Vidaud D, et al: Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res 61: 1919-1926, 2001.
25. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL and Visakorpi T Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 61: 3550-3555, 2001. (Pubitemid 32694958)
26. Neves AF, Araujo TG, Biase WK, et al: Combined analysis of multiple mRNA markers by RT-PCR assay for prostate cancer diagnosis. Clin Biochem 41: 1191-1198, 2008.
27. Samani AA, Yakar S, LeRoith D and Brodt P: The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 28: 20-47, 2007. (Pubitemid 46220849)
28. Werner H and Maor S: The insulin-like growth factor-I receptor gene: a downstream target for oncogene and tumor-suppressor action. Trends Endocrinol Metab 17: 236-242, 2006. (Pubitemid 44080616)
29. Ruan W, Powell-Braxton L, Kopchick JJ and Kleinberg DL: Evidence that insulin-like growth factor I and growth hormone are required for prostate gland development. Endocrinology 140: 1984-1989, 1999.
30. DiGiovanni J Kiguchi K, Frijhoff A, et al: Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. Proc Natl Acad Sci USA 97: 3455-3460, 2000. (Pubitemid 30183324)
31. Chan JM, Stampfer MJ, Giovannucci E, et al: Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279: 563-566, 1998. (Pubitemid 28067285)
32. Plymate SR, Tennant MK, Culp SH, et al: Androgen receptor (AR) expression in AR-negative prostate cancer cells results in differential effects of DHT and IGF-I on proliferation and AR activity between localized and metastatic tumors. Prostate 61: 276-290, 2004. (Pubitemid 39350451)
33. Schayek H, Haugk K, Sun S, True LD, Plymate SR and Werner H: Tumor suppressor BRCA1 is expressed in prostate cancer and controls insulin-like growth factor I receptor (IGF-IR) gene transcription in an androgen receptor-dependent manner. Clin Cancer Res 15: 1558-1565, 2009.
34. Hodge KK, McNeal JE, Terris MK and Stamey TA: Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 142: 71-75, 1989. (Pubitemid 19184006)
35. Vissac C, Peffault De Latour M, Communal Y, Bignon YJ and Bernard-Gallon DJ: Expression of BRCA1 and BRCA2 in different tumor cell lines with various growth status. Clin Chim Acta 320: 101-110, 2002. (Pubitemid 34450828)
36. Wong ML and Medrano JF: Real-time PCR for mRNA quantitation. Biotechniques 39: 75-85, 2005.
37. Fink L, Seeger W, Ermert L, et al: Real-time quantitative RT-PCR after laser-assisted cell picking. Nat Med 4: 1329-1333, 1998. (Pubitemid 28512117)
38. Favy DA, Lafarge S, Rio P, Vissac C, Bignon YJ and Bernard-Gallon D: Real-time PCR quantification of full-length and exon 11 spliced BRCA1 transcripts in human breast cancer cell lines. Biochem Biophys Res Commun 274: 73-78, 2000. (Pubitemid 30496759)
39. Chalabi N, Delort L, Satih S, Dechelotte P, Bignon YJ and Bernard-Gallon DJ: Immunohistochemical expression of RARalpha, RARbeta, and Cx43 in breast tumor cell lines after treatment with lycopene and correlation with RT-QPCR. J Histochem Cytochem 55: 877-883, 2007. (Pubitemid 47293833)
40. Kwiatkowski F, Girard M, Hacene K and Berlie J: [Sem: a suitable statistical software adaptated for research in oncology]. Bull Cancer 87: 715-721, 2000. (In French).
41. Harnden P, Shelley MD, Coles B, Staffurth J and Mason MD: Should the Gleason grading system for prostate cancer be modified to account for high-grade tertiary components? A systematic review and meta-analysis. Lancet Oncol 8: 411-419, 2007. (Pubitemid 46621769)
42. Lopez-Beltran A, Mikuz G, Luque RJ, Mazzucchelli R and Montironi R: Current practice of Gleason grading of prostate carcinoma. Virchows Arch 448: 111-118, 2006. (Pubitemid 43237875)
43. Edwards SM, Dunsmuir WD, Gillett CE, et al: Immunohistochemical expression of BRCA2 protein and allelic loss at the BRCA2 locus in prostate cancer. CRC/BPG UK Familial Prostate Cancer Study Collaborators. Int J Cancer 78: 1-7, 1998. (Pubitemid 28391665)
44. Thompson ME, Jensen RA, Obermiller PS, Page DL and Holt JT: Decreased expression of BRCAl accelerates growth and is often present during sporadic breast cancer progression. Nat Genet 9: 444-450, 1995.
45. Nelius T, Filleur S, Yemelyanov A, et al: Androgen receptor targets NFkappaB and TSP1 to suppress prostate tumor growth in vivo. Int J Cancer 121: 999-1008, 2007. (Pubitemid 47101635)
46. Agoulnik IU and Weigel NL: Androgen receptor action in hormone-dependent and recurrent prostate cancer. J Cell Biochem 99: 362-372, 2006. (Pubitemid 44435554)
47. Cardillo MR, Monti S, Di Silverio F, Gentile V, Sciarra F and Toscano V: Insulin-like growth factor (IGF)-I, IGF-II and IGF type I receptor (IGFR-I) expression in prostatic cancer. Anticancer Res 23: 3825-3835, 2003.